Research group - Katalin Dobra

Denna sida på svenska

We study the differentiation of malignant tumors of the lung and pleura and their molecular signature relating to biological properties such as proliferation and invasion. We identify biomarkers that allow early diagnosis and optimize conditions for individualized treatment. 

Research group leader Katalin Dobra

Senior lecturer/senior physician

Katalin Dobra

Organizational unit: Division of Pathology
E-mail: Katalin.Dobra@ki.se

Group members

Åsa-Lena DacklandAssociated
Katalin DobraSenior lecturer/senior physician
Ghazal Heidari HamedaniPhD student
Carl-Olof HillerdalPhD student
Anders HjerpeProfessor emeritus
Joman JavadiR&D trainee
Ashish Kumar SinghGraduate Student
Tunde SzatmariAssociated

Research techniques

  • Cell culture, establishment of primary cells
  • Molecular- and biochemical analyzes
  • Proteomics
  • Lighting and fluorescence microscopy
  • Ex-vivo susceptibility testing of primary tumor cells for cytotoxic substances and drugs

External funding

Research Council, the Swedish Cancer Society, AFA insurance, Heart-Lung Foundation, the Cancer Society in Stockholm, the Swedish Medical Society, Stockholm County Council (Research Fellow), KI Funds, Compass

Teaching assignments

We actively participate in the education of Medical- and Dental Student Programs and the Biomedical Analytical program

Selected publications

Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma.
Heidari-Hamedani G, Vivès R, Seffouh A, Afratis N, Oosterhof A, van Kuppevelt T, et al
Cell. Signal. 2015 Oct;27(10):2054-67

Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.
Szulkin A, Otvös R, Hillerdal C, Celep A, Yousef-Fadhel E, Skribek H, et al
BMC Cancer 2014 Sep;14():709

Nuclear translocation of heparan sulfate proteoglycans and their functional significance.
Kovalszky I, Hjerpe A, Dobra K
Biochim. Biophys. Acta 2014 Aug;1840(8):2491-7

Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
Mundt F, Johansson H, Forshed J, Arslan S, Metintas M, Dobra K, et al
Mol. Cell Proteomics 2014 Mar;13(3):701-15

Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells.
Szatmári T, Mundt F, Heidari-Hamedani G, Zong F, Ferolla E, Alexeyenko A, et al
PLoS ONE 2012 ;7(10):e48091

Lung cancerPathology